EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy

Alexander Grote iD, Dieter-Henrik Heiland, Julia Taube, Christoph Helmstaedter, Vidhya M Ravi, Paulina Will, Elke Hattingen, Jan-Rüdiger Schüre, Juri-Alexander Witt, Annika Reimers, Christian Elger, Johannes Schramm und 2 weitere

Brain · 2023

DOI: 10.1093/brain/awac293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Alexander Grote und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Neurosurgery, University Hospital of Marburg, 35033 Marburg, Germany. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Drug Resistant Epilepsy, Hippocampal Sclerosis. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-resistant mesial-temporal lobe epilepsy is a devastating disease with seizure onset in the hippocampal formation. A fraction of hippocampi samples from epilepsy-surgical procedures reveals a peculiar histological pattern referred to as ‘gliosis only’ with unresolved pathogenesis and enigmatic sequelae. Here, we hypothesize that ‘gliosis only’ represents a particular syndrome defined by distinct clinical and molecular characteristics. We curated an in-depth multiparameter integration of systematic clinical, neuropsychological as well as neuropathological analysis from a consecutive cohort of 627 patients, who underwent hippocampectomy for drug-resistant temporal lobe epilepsy. All patients underwent either classic anterior temporal lobectomy or selective amygdalohippocampectomy. On the basis of their neuropathological exam, patients with hippocampus sclerosis and ‘gliosis only’ were characterized and compared within the whole cohort and within a subset of matched pairs. Integrated transcriptional analysis was performed to address molecular differences between both groups. ‘Gliosis only’ revealed demographics, clinical and neuropsychological outcome fundamentally different from hippocampus sclerosis. ‘Gliosis only’ patients had a significantly later seizure onset (16.3 versus 12.2 years, P = 0.005) and worse neuropsychological outcome after surgery compared to patients with hippocampus sclerosis. Epilepsy was less amendable by surgery in ‘gliosis only’ patients, resulting in a significantly worse rate of seizure freedom after surgery in this subgroup (43% versus 68%, P = 0.0001, odds ratio = 2.8, confidence interval 1.7–4.7). This finding remained significant after multivariate and matched-pairs analysis. The ‘gliosis only’ group demonstrated pronounced astrogliosis and lack of significant neuronal degeneration in contrast to characteristic segmental neuron loss and fibrillary astrogliosis in hippocampus sclerosis. RNA-sequencing of gliosis only patients deciphered a distinct transcriptional programme that resembles an innate inflammatory response of reactive astrocytes. Our data indicate a new temporal lobe epilepsy syndrome for which we suggest the term ‘Innate inflammatory gliosis only’. ‘Innate inflammatory gliosis only’ is characterized by a diffuse gliosis pattern lacking restricted hippocampal focality and is poorly controllable by surgery. Thus, ‘innate inflammatory gliosis only’ patients need to be clearly identified by presurgical examination paradigms of pharmacoresistant temporal lobe epilepsy patients; surgical treatment of this subgroup should be considered with great precaution. ‘Innate inflammatory gliosis only’ requires innovative pharmacotreatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsy, Temporal LobeDrug Resistant EpilepsyHippocampal SclerosisHumansGliosisSclerosisHippocampusTemporal LobeTreatment Outcome

Stichwörter der Autor:innen

epilepsy surgerygliosis onlyinnate inflammationneuropsychologyseizure outcome

Autor:innen und Institutionen

  • Clinic for Neurosurgery, University Hospital of Marburg, 35033 Marburg, Germany.
  • Clinic for Neurosurgery, University Medical Center Freiburg, 79106 Freiburg, Germany.
  • Clinic for Epileptology, University Hospital of Bonn, 53127 Bonn, Germany.
  • Department of Neuroradiology, Hospital of Goethe University Frankfurt, 60528 Frankfurt am Main, Germany.
  • Institute of Neuropathology, Section for Translational Epilepsy Research, University Hospital of Bonn, 53127 Bonn, Germany.
  • Clinic for Neurology and Competence Center for Epilepsy, Beta Klinik Bonn GmbH, 53227 Bonn, Germany.

ORCID-Profile: Alexander Grote

Zitieren

APA

Grote, A., Heiland, D. H., Taube, J., Helmstaedter, C., Ravi, V. M., Will, P., Hattingen, E., Schüre, J. R., Witt, J. A., Reimers, A., Elger, C., Schramm, J., Becker, A. J., & Delev, D. (2023). ‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy. Brain. https://doi.org/10.1093/brain/awac293

Vancouver

Grote A, Heiland DH, Taube J, Helmstaedter C, Ravi VM, Will P, et al. ‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy. Brain. 2023. doi:10.1093/brain/awac293

BibTeX
@article{Grote2023,
  author = {Grote, Alexander and Heiland, Dieter-Henrik and Taube, Julia and Helmstaedter, Christoph and Ravi, Vidhya M and Will, Paulina and Hattingen, Elke and Schüre, Jan-Rüdiger and Witt, Juri-Alexander and Reimers, Annika and Elger, Christian and Schramm, Johannes and Becker, Albert J and Delev, Daniel},
  title = {‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy},
  journal = {Brain},
  year = {2023},
  doi = {10.1093/brain/awac293}
}
Kostenlos starten →